D-0660-2021 Class II Terminated
FDA drug recall D-0660-2021 was initiated by CIPLA on Jun 10, 2021 and is designated Class II. Reason for recall: CGMP Deviations The recall status is terminated (terminated Jan 10, 2024). Affected quantity: 7228 bottles.
Recall Details
- Product Type
- Drugs
- Report Date
- Jul 21, 2021
- Initiation Date
- Jun 10, 2021
- Termination Date
- Jan 10, 2024
- Voluntary/Mandated
- Voluntary: Firm initiated
- Product Quantity
- 7228 bottles
Product Description
Solifenacin Succinate Tablets, 10 mg, 30-count bottles, Rx Only, Manufactured by: Cipla Ltd., Verna, Goa, India Manufactured for Cipla USA, Inc. 1560 Sawgrass Corporate Parkway, Suite 130, Sunrise, FL, 33323, NDC 69097-261-02.
Reason for Recall
CGMP Deviations
Distribution Pattern
Nationwide within the United States
Code Information
Lot #: GG90819, Exp. Date 06/2021
Source
- Dataset
- openFDA drug recall enforcement reports
- FDA record
- This recall in openFDA (JSON)
- Enforcement Report
- Search FDA's Enforcement Report for D-0660-2021
- openFDA file date
- Nov 3, 2026
- Loaded by RegDataLab
- Nov 4, 2026